Clinical Research Directory

Inclusion Criteria: * Age≥ 18 and \<70 * Type 2 diabetic patients, with a duration of NPH between 5 and 10 years. * Patients treated with a double dose of NPH insulin with a stable dose of insulin and a stable dose of ADO (oral antidiabetic drugs) for at least 2 months prior to the start of the study. * An HbA1c level between 7% and 10% * Ability to use a continuous glucose monitoring (CGM) system and cycle blood glucose with the meter. * Written informed consent obtained prior to participation in the study. Exclusion Criteria: * Pregnant and breastfeeding women * Patients with active proliferative and/or complicated diabetic retinopathy, treated by photocoagulation or surgically, within 6 months prior to study entry or any other rapidly progressing unstable retinopathy that may require photocoagulation or surgery during the study (plan to perform fundus prior to inclusion). * History of insulin glargine hypersensitivity * Treatment with systemic, neuroleptic, immunosuppressive and antiretroviral corticosteroids within 3 months prior to study entry and during the study and other treatments, which may significantly affect blood glucose. * Severe renal impairment at baseline defined by a \< 30ml/min. * Patients on sulfonylurea drugs or glinides or on more than three oral antidiabetic drugs (ODAs) * Patients on rapid insulin. * Patients Enrolled in Other Clinical Studies * Patients who refuse to sign consent.